Nothing Special   »   [go: up one dir, main page]

CN108451939B - 2,4-二硝基苯磺酰胺类化合物的用途 - Google Patents

2,4-二硝基苯磺酰胺类化合物的用途 Download PDF

Info

Publication number
CN108451939B
CN108451939B CN201810457188.0A CN201810457188A CN108451939B CN 108451939 B CN108451939 B CN 108451939B CN 201810457188 A CN201810457188 A CN 201810457188A CN 108451939 B CN108451939 B CN 108451939B
Authority
CN
China
Prior art keywords
dmso
substituted
nmr
unsubstituted
100mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201810457188.0A
Other languages
English (en)
Other versions
CN108451939A (zh
Inventor
张保新
房建国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lanzhou University
Original Assignee
Lanzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanzhou University filed Critical Lanzhou University
Priority to CN201810457188.0A priority Critical patent/CN108451939B/zh
Publication of CN108451939A publication Critical patent/CN108451939A/zh
Application granted granted Critical
Publication of CN108451939B publication Critical patent/CN108451939B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了2,4‑二硝基苯磺酰胺类化合物的新用途，即2,4‑二硝基苯磺酰胺类化合物用于制备硫氧还蛋白还原酶抑制剂的用途，该类化合物为具有如下结构通式的化合物或其药学上可接受的盐：
Figure DDA0001659972080000011
其中，A为3～10元环；R为氢、取代或未取代的脂肪烃基、取代或未取代的脂环烃基、取代或未取代的脂杂环烃基、取代或未取代的芳基、取代或未取代的杂芳基；R1为取代或未取代的脂肪烃基、取代或未取代的脂环烃基、取代或未取代的脂杂环烃基、取代或未取代的芳基、取代或未取代的杂芳基。本发明可为癌症靶向治疗提供一种新的策略。

Description

2,4-二硝基苯磺酰胺类化合物的用途
技术领域
本发明属于医药领域，具体涉及2,4-二硝基苯磺酰胺类化合物的用途。
背景技术
癌症是严重威胁人类健康的常见疾病，位居人类三大主要致死疾病之首，是目前我国乃至世界范围内仍未解决的首要难题。目前，手术治疗、放射治疗与药物治疗是人类治疗癌症的三条有效途径，其中，化学药物治疗在癌症治疗中起着不可替代的作用。硫氧还蛋白还原酶(TrxR)是一种含硒蛋白，它与NADPH及它的底物硫氧还蛋白(Trx)一起构成了硫氧还蛋白系统。该系统在细胞增殖、分化和死亡等生理过程中发挥着非常重要的作用。大量研究表明，与正常组织相比，TrxR在多种肿瘤细胞中都处于过表达状态，通过化学药物抑制TrxR的活性已经成为一种有效的癌症靶向治疗策略。
发明内容
本发明的目的在于根据上述背景技术的现状，提供了2,4-二硝基苯磺酰胺类化合物在制备硫氧还蛋白还原酶抑制剂中的新用途。
为了解决上述技术问题，本发明提供了如下的技术方案：
2,4-二硝基苯磺酰胺类化合物的用途，所述2,4-二硝基苯磺酰胺类化合物为具有如下结构通式的化合物或其药学上可接受的盐：
Figure BDA0001659972060000011
Figure BDA0001659972060000021
其中，
A为3～10元环；
R为氢、取代或未取代的脂肪烃基、取代或未取代的脂环烃基、取代或未取代的脂杂环烃基、取代或未取代的芳基、取代或未取代的杂芳基；
R1为取代或未取代的脂肪烃基、取代或未取代的脂环烃基、取代或未取代的脂杂环烃基、取代或未取代的芳基、取代或未取代的杂芳基；
其特征在于，所述2,4-二硝基苯磺酰胺类化合物用于制备硫氧还蛋白还原酶抑制剂的用途。
优选地，所述A为包括0、1、2或3个O、N和/或S杂原子的5～6元环。
优选地，所述2,4-二硝基苯磺酰胺类化合物为具有如下结构式之一的化合物或其药学上可接受的盐：
Figure BDA0001659972060000022
Figure BDA0001659972060000031
Figure BDA0001659972060000041
Figure BDA0001659972060000051
Figure BDA0001659972060000061
Figure BDA0001659972060000071
一种用于抑制硫氧还蛋白还原酶的组合物，包括对硫氧还蛋白还原酶具有抑制活性的如上所述的2,4-二硝基苯磺酰胺类化合物，以及药物上可接受的辅料。
优选地，所述2,4-二硝基苯磺酰胺类化合物为具有如下结构式之一的化合物或其药学上可接受的盐：
Figure BDA0001659972060000072
Figure BDA0001659972060000073
附图说明
附图用来提供对本发明的进一步理解，并且构成说明书的一部分，与本发明的实施例一起用于解释本发明，并不构成对本发明的限制。在附图中：
图1是部分2,4-二硝基苯磺酰胺类化合物细胞外抑制硫氧还蛋白还原酶活性；
图2是化合物7细胞外对各种酶的抑制活性。
具体实施方式
以下结合附图对本发明的优选实施例进行说明，应当理解，此处所描述的优选实施例仅用于说明和解释本发明，并不用于限定本发明。
本发明的2,4-二硝基苯磺酰胺类化合物具有如下结构通式的化合物或其药学上可接受的盐：
Figure BDA0001659972060000081
其中，
A为3～10元环；
R为氢、取代或未取代的脂肪烃基、取代或未取代的脂环烃基、取代或未取代的脂杂环烃基、取代或未取代的芳基、取代或未取代的杂芳基；
R1为取代或未取代的脂肪烃基、取代或未取代的脂环烃基、取代或未取代的脂杂环烃基、取代或未取代的芳基、取代或未取代的杂芳基。
所述取代或未取代的脂肪烃基的例子如：C1-C20烷基，烯基C1-C20烷基、炔基C1-C20烷基、对乙氧基苯基C1-C20烷基、邻乙氧基苯基C1-C20烷基、间乙氧基苯基C1-C20烷基、对甲氧基苯基C1-C20烷基、邻甲氧基苯基C1-C20烷基、间甲氧基苯基C1-C20烷基、苯基C1-C20烷基、卤代苯基C1-C20烷基、萘基C1-C20烷基、呋喃基C1-C20烷基、四氢化呋喃基C1-C20烷基、哌啶基C1-C20烷基、环烷基C1-C20烷基、噻吩基C1-C20烷基、吡啶基C1-C20烷基、吡咯基C1-C20烷基、吗啉基C1-C20烷基、哌嗪基C1-C20烷基、C1-C20烷基酰基、
Figure BDA0001659972060000082
C1-C20烷氧羰基C1-C20烷基(如
Figure BDA0001659972060000083
Figure BDA0001659972060000084
)等。
所述取代或未取代的脂环烃基的例子如：环戊基、环己基、C1-C20烷基环戊基、C1-C20烷基环己基、卤代环戊基、卤代环己基、C1-C20烷氧基环戊基、C1-C20烷氧基环己基等。
所述取代或未取代的脂杂环烃基的例子如：四氢呋喃基、四氢吡喃基、四氢噻吩基、硫化环戊烷基、哌啶基、吗啉基、哌嗪基，或被一个或多个C1-C20烷基、C1-C20烷氧基、C1-C20烷氧羰基、卤原子取代的四氢呋喃基、四氢吡喃基、四氢噻吩基、硫化环戊烷基、哌啶基、吗啉基、哌嗪基等。
所述取代或未取代的芳基或杂芳基的例子如：苯基、萘基、C1-C20烷基苯基、C1-C20烷氧基苯基、C1-C20烷氧羰基苯基、卤代苯基、呋喃基、C1-C20烷基呋喃基、C1-C20烷氧基呋喃基、C1-C20烷氧羰基呋喃基、卤代呋喃基、噻吩基、C1-C20烷基噻吩基、C1-C20烷氧基噻吩基、C1-C20烷氧羰基噻吩基、卤代噻吩基、吡啶基、C1-C20烷基吡啶基、C1-C20烷氧基吡啶基、C1-C20烷氧羰基吡啶基、卤代吡啶基、吡咯基、C1-C20烷基吡咯基、C1-C20烷氧基吡咯基、C1-C20烷氧羰基吡咯基、卤代吡咯基、茚基、茚满基、胡椒环基等。
所述的卤为F、Cl、Br、I。
所述的
Figure BDA0001659972060000091
优选具有如下结构式之一：
Figure BDA0001659972060000092
Figure BDA0001659972060000101
本发明的2,4-二硝基苯磺酰胺类化合物并不局限于以下所述的具体实例。、
Figure BDA0001659972060000111
Figure BDA0001659972060000121
Figure BDA0001659972060000131
Figure BDA0001659972060000141
2,4-二硝基苯磺酰胺类化合物的制备：在氩气保护下，将1mmol的胺类化合物溶解于二氯甲烷，然后在冰浴中加入2mmol的三乙胺搅拌15min左右，之后逐滴加入2,4-二硝基苯磺酰氯(1.2mmol)二氯甲烷溶液，反应进程用TLC监测，当反应结束后加入20ml的蒸馏水，用二氯甲烷萃取三次，合并有机相，之后用无水硫酸钠干燥，最后用柱层析分离得到目标化合物。
2,4-dinitro-N-butylbenzenesulfonamide(1)1H NMR(400MHz,DMSO-d6)δ:8.88(d,J＝2.0Hz,1H),8.65(dd,J＝8.8,2.4Hz,1H),8.43(s,1H),8.24(d,J＝8.4Hz,1H),2.95(t,2H),1.44(s,2H),1.30(s,2H),0.84(t,3H)；13C NMR(100MHz,DMSO-d6)δ:150.06,148.08,138.31,131.62,127.68,120.47,42.86,31.60,19.53,13.81；mp:58-59℃.
2,4-dinitro-N-isobutylbenzenesulfonamide(2)1H NMR(400MHz,DMSO-d6)δ:8.86(d,J＝2.8Hz,1H),8.80(s,1H),8.28(dd,J＝9.6,2.4Hz,1H),7.22(d,J＝9.6Hz,1H),3.52(m,2H),1.73(m,1H),1.56(m,2H),0.95(s,3H),0.93(s,3H)；13C NMR(100MHz,DMSO-d6)δ:148.36,135.98,130.35,124.38,113.84,41.87,37.49,25.96,22.38；mp:79-80℃.
1-((2,4-dinitrophenyl)sulfonyl)piperidine(3)1H NMR(400MHz,DMSO-d6)δ:8.97(d,J＝2.0Hz,1H),8.58(dd,J＝8.8,2.4Hz,1H),8.27(d,J＝8.4Hz,1H),3.23(t,4H),1.58(t,4H),1.50(t,2H)；13C NMR(100MHz,DMSO-d6)δ:149.64,148.30,137.87,132.54,125.87,119.61,47.02,25.50,23.45；mp:138-139℃.
1-((2,4-dinitrophenyl)sulfonyl)-2-methylpiperidine(4)1H NMR(400MHz,DMSO-d6)δ:8.93(d,J＝2.4Hz,1H),8.58(dd,J＝8.8,2.4Hz,1H),8.34(d,J＝8.8Hz,1H),4.17(d,J＝3.2Hz,1H),3.64(dd,J＝13.6,3.2Hz,1H),3.20(m,1H),1.63(m,5H),1.32(m,1H),1.15(d,J＝6.8Hz,3H)；13C NMR(100MHz,DMSO-d6)δ:149.51,139.74,132.42,126.07,119.80,49.83,41.22,30.33,25.51,17.91,16.25；mp:121-122℃.
1-((2,4-dinitrophenyl)sulfonyl)-3-methylpiperidine(5)1H NMR(400MHz,DMSO-d6)δ:8.97(d,J＝2.0Hz,1H),8.58(dd,J＝8.8,2.0Hz,1H),8.28(d,J＝8.4Hz,1H),3.64(m,2H),2.79(m,1H),2.48(t,1H),1.73(m,2H),1.64(m,1H),1.49(m,1H),1.06(m,1H),0.87(d,J＝6.4Hz,3H)；13C NMR(100MHz,DMSO-d6)δ:149.62,137.96,132.52,125.89,119.60,52.99,46.54,31.99,31.02,25.00,18.73；mp:135-136℃.
1-((2,4-dinitrophenyl)sulfonyl)-4-methylpiperidine(6)1H NMR(400MHz,DMSO-d6)δ:8.97(d,J＝2.0Hz,1H),8.58(dd,J＝8.8,2.4Hz,1H),8.27(d,J＝8.8Hz,1H),3.72(d,J＝12.4Hz,2H),2.80(m,2H),1.71(m,2H),1.49(m,1H),1.17(m,2H),0.89(d,J＝6.4Hz,3H)；13C NMR(100MHz,DMSO-d6)δ:149.63,137.94,132.53,125.88,119.62,46.47,33.62,30.15,21.43；mp:134-135℃.
4-((2,4-dinitrophenyl)sulfonyl)morpholine(7)1H NMR(400MHz,DMSO-d6)δ:9.00(d,J＝2.4Hz,1H),8.60(dd,J＝8.8,2.4Hz,1H),8.28(d,J＝8.8Hz,1H),3.67(t,4H),3.24(t,4H)；13C NMR(100MHz,DMSO-d6)δ:150.69,148.32,134.25,132.77,127.34,120.47,65.97,46.17；mp:143-144℃.
1-((2,4-dinitrophenyl)sulfonyl)pyrrolidine(8)1H NMR(400MHz,DMSO-d6)δ:8.86(d,J＝2.8Hz,1H),8.48(d,J＝6.8Hz,1H),8.29(dd,J＝9.6,2.4Hz,1H),7.29(d,J＝9.6Hz,1H),4.27(m,1H),2.14(m,2H),1.76(m,2H),1.68(m,4H)；13C NMR(100MHz,DMSO-d6)δ:147.91,135.87,130.34,130.14,124.43,114.61,54.76,33.47,24.00；mp:67-68℃
2,4-dinitro-N-benzylbenzenesulfonamide(9)1H NMR(400MHz,DMSO-d6)δ:9.02(t,1H),8.85(d,J＝2.0Hz,1H),8.52(dd,J＝8.8,2.0Hz,1H),8.13(d,J＝8.8Hz,1H),7.28(m,5H),4.22(d,J＝6.0Hz,2H)；13C NMR(100MHz,DMSO-d6)δ:149.88,147.82,138.51,137.34,131.77,129.09,128.73,128.09,127.80,127.45,127.33,120.37,46.72；mp:136-137℃.
2,4-dinitro-N-(2-methoxybenzyl)benzenesulfonamide(10)1H NMR(400MHz,DMSO-d6)δ:8.83(d,J＝2.0Hz,1H),8.76(s,1H),8.52(dd,J＝8.8,2.0Hz,1H),8.09(d,J＝8.4Hz,1H),7.21(m,2H),6.87(m,2H),4.17(s,3H),3.68(s,3H)；13C NMR(100MHz,DMSO-d6)δ:157.28,149.16,147.36,140.08,132.76,130.42,129.93,126.48,123.35,120.12,120.00,109.86,55.15,45.42；mp:156-157℃.
2,4-dinitro-N-(3-methoxybenzyl)benzenesulfonamide(11)1H NMR(400MHz,DMSO-d6)δ:8.99(s,1H),8.85(d,J＝2.0Hz,1H),8.50(dd,J＝8.8,2.4Hz,1H),8.11(d,J＝8.8Hz,1H),7.17(t,1H),6.81(m,3H),4.18(s,2H),3.67(s,3H)；13C NMR(100MHz,DMSO-d6)δ:159.80,149.49,147.69,139.62,136.68,132.49,129.87,126.66,120.34,120.15,113.85,113.31,55.20,48.01；mp:101-102℃.
2,4-dinitro-N-(4-methoxybenzyl)benzenesulfonamide(12)1H NMR(400MHz,DMSO-d6)δ:8.91(s,1H),8.83(d,J＝2.0Hz,1H),8.50(dd,J＝8.4,2.0Hz,1H),8.07(d,J＝8.8Hz,1H),7.14(d,J＝8.4Hz,2H),6.79(d,J＝8.4Hz,2H),4.14(d,J＝4.4Hz,2H),3.68(s,3H)；13C NMR(100MHz,DMSO-d6)δ:159.07,149.77,147.75,138.65,131.83,129.59,129.17,127.35,120.30,114.10,55.48,46.32；mp:157-158℃.
1-((2,4-dinitrophenyl)sulfonyl)-1H-pyrrole(13)1HN MR(400MHz,DMSO-d6)δ:12.03(s,1H),8.93(dd,J＝8.4,2.0Hz,1H),8.86(d,J＝2.4Hz,1H),8.64(d,J＝8.8Hz,1H),7.03(d,J＝1.2Hz,1H),6.29(m,1H),6.12(m,1H)；13C NMR(100MHz,DMSO-d6)δ:149.38,148.90,144.95,129.97,129.85,128.46,124.25,121.05,113.42,109.59；mp:148-149℃.
1-((2,4-dinitrophenyl)sulfonyl)-1H-benzo[d]imidazole(14)1H NMR(400MHz,DMSO-d6)δ:9.00(s,1H),8,76(s,1H),8.72(d,J＝8.8Hz,1H),8.65(dd,J＝8.8,2.4Hz,1H),7.86(m,2H),7.52(m,2H)；13C NMR(100MHz,DMSO-d6)δ:152.01,147.94,143.75,142.88,133.58,133.01,130.26,128.44,126.59,126.03,121.79,121.51,112.90；mp:182-184℃.
2,4-dinitro-N-(pyridin-2-yl)benzenesulfonamide(15)1H NMR(400MHz,DMSO-d6)δ:10.33(s,1H),8.81(d,J＝2.4Hz,1H),8.46(m,2H),8.31(dd,J＝4.8,1.2Hz,1H),7.85(m,1H),7.28(d,J＝8.4Hz,1H),7.15(m,1H)；13C NMR(100MHz,DMSO-d6)δ:152.21,148.12,143.37,138.77,138.65,132.67,129.82,123.08,119.79,119.75,115.06；mp:153-154℃.
2,4-dinitro-N-(naphthalen-1-yl)benzenesulfonamide(16)1H NMR(400MHz,DMSO-d6)δ:11.02(s,1H),8.89(d,J＝1.6Hz,1H),8.51(dd,J＝8.8,2.4Hz,1H),8.04(d,J＝8.8Hz,2H),7.95(m,2H),7.52(m,3H),7.30(d,J＝7.2Hz,1H)；13C NMR(100MHz,DMSO-d6)δ:150.35,147.81,137.42,134.36,132.32,131.15,130.39,128.54,128.39,127.46,127.02,126.88,126.06,125.33,120.60；mp:167-168℃.
2,4-dinitro-N-(4-ethoxycarbonylphenyl)benzenesulfonamide(17)1H NMR(400MHz,DMSO-d6)δ:11.56(s,1H),8.90(s,1H),8.60(d,J＝8.8Hz,1H),8.28(dd,J＝8.4,1.6Hz,1H),7.89(t,3H),7.27(t,3H),4.29(m,2H),1.29(t,3H)；13C NMR(100MHz,DMSO-d6)δ:165.43,150.65,148.23,141.07,136.30,132.13,131.43,131.15,127.80,126.33,120.92,119.80,61.07,14.56；mp:183-184℃.
2,4-dinitro-N-phenylbenzenesulfonamide(18)1H NMR(400MHz,DMSO-d6)δ:8.88(d,J＝2.0Hz,1H),8.60(dd,J＝8.8,2.4Hz,1H),8.22(d,J＝8.8Hz,1H),7.32(t,2H),7.15(m,3H)；13C NMR(100MHz,DMSO-d6)δ:150.46,148.28,136.74,136.38,132.00,129.89,127.63,125.74,121.54,120.74；mp:110-111℃.
2,4-dinitro-N-(2-tolyl)benzenesulfonamide(19)1H NMR(400MHz,DMSO-d6)δ:10.35(s,1H),8.91(d,J＝2.0Hz,1H),8.58(dd,J＝8.8,2.4Hz,1H),8.02(d,J＝8.8Hz,1H),7.23(m,3H),7.02(d,J＝7.6Hz,1H),2.10(m,3H)；13C NMR(100MHz,DMSO-d6)δ:149.99,148.24,138.71,133.79,133.11,132.88,131.49,127.93,127.12,126.88,125.64,120.66,17.89；mp:151-152℃.
2,4-dinitro-N-(3-tolyl)benzenesulfonamide(20)1H NMR(400MHz,DMSO-d6)δ:10.96(s,1H),8.88(d,J＝2.4Hz,1H),8.61(dd,J＝8.8,2.4Hz,1H),8.21(d,J＝8.8Hz,1H),7.19(t,1H),6.96(t,3H),2.23(s,3H)；13C NMR(100MHz,DMSO-d6)δ:150.03,148.48,139.98,137.75,134.41,133.51,129.50,128.09,126.73,124.02,120.62,120.22,21.30；mp:140-141℃.
2,4-dinitro-N-(4-tolyl)benzenesulfonamide(21)1H NMR(400MHz,DMSO-d6)δ:10.82(s,1H),8.87(d,J＝2.4Hz,1H),8.60(dd,J＝8.8,2.4Hz,1H),8.18(d,J＝8.8Hz,1H),7.11(d,J＝8.4Hz,2H),7.03(d,J＝8.4Hz,2H),2.21(s,3H)；13C NMR(100MHz,DMSO-d6)δ:150.40,148.30,136.80,135.28,133.62,132.01,130.30,127.56,122.16,120.69,20.76；mp:120-121℃.
2,4-dinitro-N-(2-methoxyphenyl)benzenesulfonamide(22)1H NMR(400MHz,DMSO-d6)δ:10.25(s,1H),8.86(d,J＝2.4Hz,1H),8.62(dd,J＝8.8,2.0Hz,1H),8.15(d,J＝8.8Hz,1H),7.26(m,1H),7.19(m,1H),6.97(m,2H),3.44(s,3H)；13C NMR(100MHz,DMSO-d6)δ:150.76,138.68,132.99,127.31,126.65,123.99,123.67,121.35,120.68,110.93,55.71；mp:172-173℃.
2,4-dinitro-N-(3-methoxyphenyl)benzenesulfonamide(23)1H NMR(400MHz,DMSO-d6)δ:11.06(s,1H),8.89(d,J＝2.4Hz,1H),8.62(dd,J＝8.8,2.4Hz,1H),8.23(d,J＝8.8Hz,1H),7.22(t,1H),6.72(m,3H),3.69(s,3H)；13C NMR(100MHz,DMSO-d6)δ:160.56,133.55,130.47,130.10,126.73,120.61,115.02,112.50,109.28,107.96,104.04,101.14,55.09；mp:156-157℃.
2,4-dinitro-N-(4-methoxyphenyl)benzenesulfonamide(24)1H NMR(400MHz,DMSO-d6)δ:11.64(s,1H),8.86(s,1H),8.59(d,J＝7.2Hz,1H),8.14(d,J＝7.6Hz,1H),7.06(d,J＝6.8Hz,2H),6.87(d,J＝6.8Hz,2H),3.69(s,3H)；13C NMR(100MHz,DMSO-d6)δ:157.85,150.35,148.26,136.85,132.10,128.51,127.48,125.12,120.59,115.02,55.68；mp:136-137℃.
2,4-dinitro-N-(2,5-dimethoxyphenyl)benzenesulfonamide(25)1H NMR(400MHz,DMSO-d6)δ:10.30(s,1H),8.87(d,J＝2.4Hz,1H),8.62(dd,J＝8.4,2.0Hz,1H),8.17(d,J＝8.8Hz,1H),6.91(d,J＝8.8Hz,1H),6.82(m,2H),3.68(s,3H),3.40(s,3H)；13CNMR(100MHz,DMSO-d6)δ:153.97,144.70,138.55,133.05,126.70,124.67,120.72,111.70,111.49,109.53,56.22,55.84；mp:140-141℃.
2,4-dinitro-N-(2-chlorophenyl)benzenesulfonamide(26)1H NMR(400MHz,DMSO-d6)δ:10.82(s,1H),8.90(d,J＝2.4Hz,1H),8.61(dd,J＝8.4,2.0Hz,1H),8.12(d,J＝8.8Hz,1H),7.49(m,1H),7.35(m,2H),7.28(m,1H)；13C NMR(100MHz,DMSO-d6)δ:150.18,148.21,138.38,132.56,131.93,129.85,128.19,128.04,127.33,127.02,126.07,121.01；mp:134-135℃.
2,4-dinitro-N-(3-chlorophenyl)benzenesulfonamide(27)1H NMR(400MHz,DMSO-d6)δ:11.16(s,1H),8.90(d,J＝2.4Hz,1H),8.63(dd,J＝8.8,2.4Hz,1H),8.26(d,J＝8.8Hz,1H),7.36(m,1H),7.21(m,2H),7.12(m,1H)；13C NMR(100MHz,DMSO-d6)δ:150.64,148.26,138.01,136.34,134.08,132.01,131.63,127.83,125.46,120.87,120.63,119.45；mp:153-154℃.
2,4-dinitro-N-(2-fluorophenyl)benzenesulfonamide(28)1H NMR(400MHz,DMSO-d6)δ:10.91(s,1H),8.90(d,J＝2.0Hz,1H),8.64(dd,J＝8.8,2.4Hz,1H),8.19(d,J＝8.8Hz,1H),7.35(m,1H),7.27(m,2H),7.21(m,1H)；13C NMR(100MHz,DMSO-d6)δ:158.47,155.99,150.65,148.08,137.73,132.25,129.67,129.60,129.03,127.83,125.62,123.23,120.80,117.05,116.86；mp:160-162℃.
2,4-dinitro-N-(3-fluorophenyl)benzenesulfonamide(29)1H NMR(400MHz,DMSO-d6)δ:11.34(s,1H),8.90(d,J＝2.0Hz,1H),8.62(dd,J＝8.8,2.4Hz,1H),8.27(d,J＝8.8Hz,1H),7.38(m,1H),6.98(m,3H)；13C NMR(100MHz,DMSO-d6)δ:163.88,161.45,150.62,148.26,136.35,132.02,131.77,131.67,127.80,120.85,116.80,112.33,112.13,108.03,107.78；mp:160-162℃.
2,4-dinitro-N-(4-fluorophenyl)benzenesulfonamide(30)1H NMR(400MHz,DMSO-d6)δ:10.99(s,1H),8.88(d,J＝2.0Hz,1H),8.61(dd,J＝8.4,2.0Hz,1H),8.19(d,J＝8.8Hz,1H),7.16(s,2H),7.15(s,2H)；13C NMR(100MHz,DMSO-d6)δ:161.48,159.06,150.49,148.23,136.53,132.46,132.08,127.63,124.73,124.64,120.69,116.78,116.56；mp:127-128℃.
实施例1 2,4-二硝基苯磺酰胺类化合物对HeLa细胞的细胞毒活性
药物：上述所制备的目标化合物1～30。
实验方法：于96孔板中，每孔加入5000个细胞，之后用不同浓度的不同的药物作用细胞72h，最后用MTT法测定细胞毒活性，计算化合物的IC50值。
表1.所有化合物在HeLa细胞中的细胞毒活性
Figure BDA0001659972060000201
实施例2 2,4-二硝基苯磺酰胺类化合物体外抑制硫氧还蛋白还原酶活性
药物：选取上述对HeLa细胞具有较高细胞毒性的目标化合物2,3,4,7,8,10,11,12。
实验方法：将还原型烟酰胺腺嘌呤二核苷磷酸(NADPH)、缓冲溶液(TE)和硫氧还蛋白还原酶(TrxR)在室温作用5min后，接着将药物(所有药物的浓度固定为50nM)加入到96孔板中，总体积为50μL，重复两个，在室温下孵育一定的时间后加入50μL含有DTNB和NADPH的混合液于每孔中，然后立即测定前4min内412nm吸光度值的增加，10s读一次数，共25次。以最大浓度的DMSO作为对照，活性用相比对照的百分比来表示，结果如图1所示。
实验结果表明目标化合物2,3,4,7,8,10,11,12在体外均能够很好的抑制硫氧还蛋白还原酶的活性。
目标化合物2,3,4,7,8,10,11,12的结构式分别如下：
Figure BDA0001659972060000202
Figure BDA0001659972060000211
实施例3 2,4-二硝基苯磺酰胺类化合物体外对各种酶的抑制活性
药物：以上述目标化合物7
Figure BDA0001659972060000212
为例。
实验方法：按照文献“Dongzhu Duan,Baoxin Zhang,Juan Yao,Yaping Liu,JinyuSun,Chunpo Ge,Shoujiao Peng,Jianguo Fang；Free Radical Biol.Med.2014,69,15-25”的方法测定化合物7在体外对各种酶活性的抑制情况(U498C TrxR：该酶是将TrxR的498位的Sec突变为Cys。GR:谷胱甘肽还原酶，该酶是一种与TrxR拥有相似结构的酶，同时也是谷胱甘肽系统的重要组成部分。GPx：谷胱甘肽过氧化物酶，是一种含硒半胱氨酸的酶)。结果如图2所示。
实验结果说明化合物7是通过选择性作用硒半胱氨酸来抑制硫氧还蛋白还原酶的活性。
最后应说明的是：以上所述仅为本发明的优选实施例而已，并不用于限制本发明，尽管参照前述实施例对本发明进行了详细的说明，对于本领域的技术人员来说，其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。

Claims (1)

1.2,4-二硝基苯磺酰胺类化合物用于制备治疗子宫颈癌药物的用途，所述2,4-二硝基苯磺酰胺类化合物结构式如下：
Figure FDF0000012958590000011
CN201810457188.0A 2018-05-14 2018-05-14 2,4-二硝基苯磺酰胺类化合物的用途 Expired - Fee Related CN108451939B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810457188.0A CN108451939B (zh) 2018-05-14 2018-05-14 2,4-二硝基苯磺酰胺类化合物的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810457188.0A CN108451939B (zh) 2018-05-14 2018-05-14 2,4-二硝基苯磺酰胺类化合物的用途

Publications (2)

Publication Number Publication Date
CN108451939A CN108451939A (zh) 2018-08-28
CN108451939B true CN108451939B (zh) 2021-11-16

Family

ID=63215221

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810457188.0A Expired - Fee Related CN108451939B (zh) 2018-05-14 2018-05-14 2,4-二硝基苯磺酰胺类化合物的用途

Country Status (1)

Country Link
CN (1) CN108451939B (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105308031A (zh) * 2013-03-04 2016-02-03 加拿大高级医学研究协会 喹啉磺酰基衍生物及其用途
KR20160032914A (ko) * 2014-09-17 2016-03-25 이화여자대학교 산학협력단 벤젠설폰아미드 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE503195C2 (sv) * 1994-08-31 1996-04-15 Electrolux Ab Morfolindiamin, interfaspolymer baserad på denna amin, membran med osmotiska egenskaper innefattande denna polymer, sätt att framställa membranet samt användning av detta vid vattenrening.
EP1489069A3 (en) * 1999-09-28 2005-01-19 E.I. du Pont de Nemours and Company Preparation of sulfonyl imine compounds
US6380429B1 (en) * 1999-09-28 2002-04-30 E. I. Du Pont Nemours And Company Preparation of sulfonyl imine compounds
EP3103791B1 (en) * 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US9079870B2 (en) * 2012-10-31 2015-07-14 Indian Institute Of Science Education And Research-Pune Thiol mediated/activated prodrugs of sulfur dioxide (SO2) having anti-bacterial activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105308031A (zh) * 2013-03-04 2016-02-03 加拿大高级医学研究协会 喹啉磺酰基衍生物及其用途
KR20160032914A (ko) * 2014-09-17 2016-03-25 이화여자대학교 산학협력단 벤젠설폰아미드 화합물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aromatic Sulfonamides Containing a Condensed Piperidine Moiety as Potential Oxidative Stress-Inducing Anticancer Agents;Ramóna Madácsi,et al.;《Medicinal Chemistry》;20131231;第9卷;第911-919页 *

Also Published As

Publication number Publication date
CN108451939A (zh) 2018-08-28

Similar Documents

Publication Publication Date Title
EP0366061B1 (de) Die Verwendung von 4H-1-Benzopyran-4-on-Derivaten, neue 4H-1-Benzopyran-4-on-Derivate und diese enthaltende Arzneimittel
EP1423388B1 (en) 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
EP1506193B1 (de) Carbamat-substituierte pyrazolopyridine
JP4500055B2 (ja) ピラゾロ［１，５−ａ］ピリミジン誘導体およびそれを含有するＮＡＤ（Ｐ）Ｈオキシダーゼ阻害剤
Bekhit et al. Novel milrinone analogs of pyridine-3-carbonitrile derivatives as promising cardiotonic agents
EP3459937B1 (en) Thiazole derivative and applications
EP1370260B1 (en) Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
MXPA04007744A (es) Nuevos derivados de piridina y pirimidina.
AU6571200A (en) Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
EP1648564B1 (en) Cyanoamide compounds useful as malonyl-coa decarboxylase inhibitors
JP2003506362A (ja) Ｇｓｋ−３阻害剤としてのジアミノ−１，２，４−トリアゾール−カルボン酸誘導体
US20040009993A1 (en) Pyridopyrimidinones derivatives as telomerase inhibitors
EP3530657B1 (en) 2-polysubstituted aromatic ring-pyrimidine derivative and preparation and medical use
WO2002065979A2 (en) (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
EP1653944A1 (en) Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
US8110686B2 (en) Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
Hester et al. N-[(. omega.-Amino-1-hydroxyalkyl) phenyl] methanesulfonamide derivatives with class III antiarrhythmic activity
EP1486488B1 (en) Use of a compound of formula I for making a pharmaceutical composition
RU2497811C2 (ru) Фенилимидазольные соединения
CN108451939B (zh) 2,4-二硝基苯磺酰胺类化合物的用途
KR100980328B1 (ko) 단백질 포스파타제의 활성을 억제하는트리아졸릴-티오-에타논 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암 예방 및 치료용조성물
KR100936278B1 (ko) 단백질 포스파타제의 활성을 억제하는 피리미딘 유도체또는 이의 약학적으로 허용가능한 염을 유효성분으로함유하는 암 예방 및 치료용 조성물
KR100998572B1 (ko) 단백질 포스파타제의 활성을 억제하는 페닐아미노티아졸론유도체 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 암 예방 및 치료용 조성물
EP2137165B1 (en) Inhibitors of protein kinases
EP1633754B1 (en) Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211116

CF01 Termination of patent right due to non-payment of annual fee